{"disease":{"id":"relapsed-or-refractory-multiple-myeloma-in-combination-with-dexamethasone-and-daratumumab-and-carfilzomib-and-isatuximab-and-elotuzumab-and-ixazomib-and-bortezomib-and-pomalidomide-and-lenalidomide-and-pf-06863135-and-bortezomib-and-ixazomib-and-carfilzomib-and-daratumumab-and-isatuximab-and-elotuzumab-and-ixazomib-and-carfilzomib-and-daratumumab-and-isatuximab-and-elotuzumab-and-ixazomib-and-carfilzomib-and-daratumumab-and-isatuximab-and-elotuzumab-and-ixazomib-and-carfilzomib.md","name":"relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and pf 06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib.md"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}